Atezolizumab - Biologic Drug Details

Summary for atezolizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for atezolizumab

Recent Clinical Trials for atezolizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Washington	PHASE2
Syntrix Biosystems, Inc.	PHASE2
Bristol-Myers Squibb	PHASE1

See all atezolizumab clinical trials

Pharmacology for atezolizumab

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody
Chemical Structure	Antibodies Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for atezolizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for atezolizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-08-18	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-04-17	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-19	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-03-06	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-06-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2034-09-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for atezolizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-06-24	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-04-06	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-09-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-11-21	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-11-06	Patent claims search

International Patents for atezolizumab

Country	Patent Number	Estimated Expiration
Israel	278007
Taiwan	202417499
Hungary	S2400018
Portugal	1537878
Croatia	P20240240
Japan	5885764
Dominican Republic	P2018000045

Supplementary Protection Certificates for atezolizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
LUC00345	Luxembourg		PRODUCT NAME: ATEZOLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1220 20170925
2016C/001	Belgium		PRODUCT NAME: KEYTRUDA (PEMBROLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/15/1024 20150721
122025000023	Germany		PRODUCT NAME: ATEZOLIZUMAB; REGISTRATION NO/DATE: EU/1/17/1220 20170921
C20240020	Finland
SPC/GB16/001	United Kingdom		PRODUCT NAME: PEMBROLIZUMAB; REGISTERED: UK EU/1/15/1024 20150721
59/2017	Austria		PRODUCT NAME: ATEZOLIZUMAB; REGISTRATION NO/DATE: EU/1/17/1220/001 (MITTEILUNG) 20170925
C201830011	Spain		PRODUCT NAME: ATEZOLIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1220; DATE OF AUTHORISATION: 20170921; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1220; DATE OF FIRST AUTHORISATION IN EEA: 20170921

Market Dynamics and Financial Trajectory for Atezolizumab

Last updated: March 5, 2026

What is the current market position of atezolizumab?

Atezolizumab (brand name Tecentriq) is a programmed death-ligand 1 (PD-L1) inhibitor approved for multiple indications, including non-small cell lung cancer (NSCLC), bladder cancer, small cell lung cancer (SCLC), and certain breast cancers. Developed by Roche, it gained FDA approval in 2016.

As of 2023, atezolizumab is one of the leading immune checkpoint inhibitors, competing mainly with pembrolizumab (Keytruda) and nivolumab (Opdivo). Its global sales peaked at approximately $2.1 billion in 2022, representing a 10% increase over 2021.

How do market factors influence atezolizumab's growth?

Competitive landscape

• Key competitors: Pembrolizumab and nivolumab.
• Market share (2022): Pembrolizumab (about 45%), nivolumab (around 25%), atezolizumab (16%), others (14%).
• Impacts: The entry of next-generation PD-1/PD-L1 inhibitors and combination regimens pressure atezolizumab's market share.

Regulatory approvals and indications

• Current approvals cover 8 indications, with ongoing trials expanding the label.
• Fast-growing indications such as triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC) could drive sales.

Reimbursement and pricing

• Price per treatment cycle varies by indication, averaging USD 10,000–20,000.
• Access depends heavily on reimbursement policies, which differ regionally.

Geographic expansion

• North America (dominates): 60% of sales in 2022.
• Europe: regulatory approvals in multiple countries.
• Asia-Pacific: rapid growth due to increasing cancer incidence and expanding access.

Patent status and biosimilar threat

• Patent protection valid until 2028.
• Biosimilar development remains limited, reducing immediate generic threat but possible in late 2020s.

What are the financial projections for atezolizumab?

Revenue forecasts

• Expected compound annual growth rate (CAGR): 8%-10% through 2027.
• Revenue estimates: reaching approximately USD 3 billion by 2027, driven by new indications and durable market presence.

Research and development expenditures

• Roche invests approximately USD 3.5 billion annually on oncology R&D.
• Significant expenses allocated to Phase III trials for novel indications and combination therapies.

Profitability analysis

• Gross margins: approximately 65-70%.
• Operating margins: around 25-30%, factoring in R&D and commercialization costs.
• Market expansion and label expansions could improve profitability metrics.

Impact of upcoming patent expiry

• Patent expiry in 2028 risks loosening market exclusivity.
• Roche’s strategy includes developing combination therapies and expanding indications to counteract biosimilar entry.

How do regulatory and market trends shape future growth?

• Accelerated approval pathways for combination therapies could reduce development timelines.
• Growing adoption in early-line settings increases potential revenue.
• Competition from emerging immunotherapies (e.g., LAG-3, TIGIT inhibitors) may impact future sales.

Summary table: Atezolizumab market summary (2022 estimates)

Factor	Data
Peak global sales	USD 2.1 billion
Market share (2022)	16%
Key indications	NSCLC, SCLC, bladder, breast cancer
Geographic distribution	North America (60%), Europe, Asia-Pacific
Patent expiry	2028
R&D budget (annual)	USD 3.5 billion
Projected 2027 revenue	USD 3 billion

Key Takeaways

• Atezolizumab's legacy relies on broad indication approval, especially in lung and bladder cancers.
• Market growth depends on competition, regulatory expansion, and regional reimbursement policies.
• Patent expiration in 2028 presents a potential challenge but can be mitigated through label expansion.
• Roche’s focus on combination therapies and new indications sustains its market position.
• Revenue growth projections remain positive, with CAGR estimates of 8%-10% up to 2027.

FAQs

Q1: What are the primary indications driving atezolizumab sales?
A1: Non-small cell lung cancer, bladder cancer, and small cell lung cancer are the main growth drivers.

Q2: How does competition affect atezolizumab’s market share?
A2: Pembrolizumab and nivolumab hold larger shares, limiting atezolizumab’s growth. New therapies or combinations could alter this landscape.

Q3: What impact will patent expiry in 2028 have?
A3: Biosimilars could enter the market, potentially reducing prices and sales unless Roche expands indications or develops next-generation therapies.

Q4: How do regional differences influence revenue?
A4: North America accounts for the majority; expansion into Europe and Asia-Pacific is critical for growth.

Q5: Are there upcoming regulatory pathways that could boost atezolizumab’s sales?
A5: Yes, accelerated approvals for combination regimens and new indications could enhance market penetration.

---

References

[1] GlobalData. (2023). Oncology immunotherapy market report 2022.
[2] Roche. (2022). Tecentriq product data sheet and annual report.
[3] IQVIA. (2022). Global Oncology Market Report.
[4] FDA. (2023). Approved drug labels for atezolizumab.